Novel BTK Inhibitor Looks Good for Sjogren's Syndrome
MedPage Today,
Meeting Coverage > ACR Phase II data show good efficacy by objective measures, even with strong placebo effect by John Gever…
Meeting Coverage > ACR Phase II data show good efficacy by objective measures, even with strong placebo effect by John Gever…
A recent review summarized the current landscape of Bruton tyrosine kinase (BTK) inhibitors in both hematological cancers and…